Your prediction
Recce Pharmaceuticals Ltd. Stock
Recce Pharmaceuticals Ltd. dominated the market today, gaining €0.010 (3.050%).
Pros and Cons of Recce Pharmaceuticals Ltd. in the next few years
Pros
?
G***** c******* t* c**********
?
B****
?
W********* I********* f** t** n*** y****
Cons
?
M***** P*******
?
C******** o* t** e**********
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
News
Hong Kong Patent Granted for RECCE® Anti-Infectives
Sydney Australia, 27 November 2025: Recce Pharmaceuticals Limited (ASX:RCE, FSE:R9Q), (Recce or the Company) a leading developer of a New Class of Synthetic Anti-Infectives, is pleased to
Positive Efficacy Data of Inhaled RECCE® 327 in Hospital/Ventilator-Acquired Pneumonia (HAP/VAP) in Mice Models
Highlights:
- RECCE® 327 (R327) demonstrated significant antibacterial activity against multidrug-resistant Acinetobacter baumannii (A. baumannii), one of the most challenging
Patient Dosing and Multiple Sites Activated in Registrational Phase 3 Clinical Trial for Diabetic Foot Infections in Indonesia
Highlights:
- Patient dosing is underway for Registrational Phase 3 Clinical Trial for Diabetic Foot Infections (DFI), with five (5) clinical study sites now activated across one